Literature DB >> 22593543

The death receptor 3/TL1A pathway is essential for efficient development of antiviral CD4⁺ and CD8⁺ T-cell immunity.

Jason P Twohig1, Morgan Marsden, Simone M Cuff, John R Ferdinand, Awen M Gallimore, William V Perks, Aymen Al-Shamkhani, Ian R Humphreys, Eddie C Y Wang.   

Abstract

Death receptor 3 (DR3, TNFRSF25), the closest family relative to tumor necrosis factor receptor 1, promotes CD4(+) T-cell-driven inflammatory disease. We investigated the in vivo role of DR3 and its ligand TL1A in viral infection, by challenging DR3-deficient (DR3(KO)) mice and their DR3(WT) littermates with the β-herpesvirus murine cytomegalovirus or the poxvirus vaccinia virus. The phenotype and function of splenic T-cells were analyzed using flow cytometry and molecular biological techniques. We report surface expression of DR3 by naive CD8(+) T cells, with TCR activation increasing its levels 4-fold and altering the ratio of DR3 splice variants. T-cell responses were reduced up to 90% in DR3(KO) mice during acute infection. Adoptive transfer experiments indicated this was dependent on T-cell-restricted expression of DR3. DR3-dependent CD8(+) T-cell expansion was NK and CD4 independent and due to proliferation, not decreased cell death. Notably, impaired immunity in DR3(KO) hosts on a C57BL/6 background was associated with 4- to 7-fold increases in viral loads during the acute phase of infection, and in mice with suboptimal NK responses was essential for survival (37.5%). This is the first description of DR3 regulating virus-specific T-cell function in vivo and uncovers a critical role for DR3 in mediating antiviral immunity.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22593543      PMCID: PMC3460213          DOI: 10.1096/fj.11-200618

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  68 in total

1.  TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator.

Authors:  Thi Sau Migone; Jun Zhang; Xia Luo; Li Zhuang; Cecil Chen; Bugen Hu; June S Hong; James W Perry; Su Fang Chen; Joe X H Zhou; Yun Hee Cho; Stephen Ullrich; Palanisamy Kanakaraj; Jeffrey Carrell; Ernest Boyd; Henrik S Olsen; Gang Hu; Laurie Pukac; Ding Liu; Jian Ni; Sunghee Kim; Reiner Gentz; Ping Feng; Paul A Moore; Steve M Ruben; Ping Wei
Journal:  Immunity       Date:  2002-03       Impact factor: 31.745

2.  DR3 regulates negative selection during thymocyte development.

Authors:  E C Wang; A Thern; A Denzel; J Kitson; S N Farrow; M J Owen
Journal:  Mol Cell Biol       Date:  2001-05       Impact factor: 4.272

3.  Differential B7-CD28 costimulatory requirements for stable and inflationary mouse cytomegalovirus-specific memory CD8 T cell populations.

Authors:  Ramon Arens; Andrea Loewendorf; Anke Redeker; Sophie Sierro; Louis Boon; Paul Klenerman; Chris A Benedict; Stephen P Schoenberger
Journal:  J Immunol       Date:  2011-02-28       Impact factor: 5.422

4.  The adaptor protein TRADD is essential for TNF-like ligand 1A/death receptor 3 signaling.

Authors:  Yelena L Pobezinskaya; Swati Choksi; Michael J Morgan; Xiumei Cao; Zheng-gang Liu
Journal:  J Immunol       Date:  2011-03-18       Impact factor: 5.422

5.  DR3 signaling protects against cisplatin nephrotoxicity mediated by tumor necrosis factor.

Authors:  Rafia S Al-Lamki; WanHua Lu; Sarah Finlay; Jason P Twohig; Eddie C Y Wang; Aviva M Tolkovsky; John R Bradley
Journal:  Am J Pathol       Date:  2012-02-11       Impact factor: 4.307

6.  Sustained TL1A expression modulates effector and regulatory T-cell responses and drives intestinal goblet cell hyperplasia.

Authors:  V Y Taraban; T J Slebioda; J E Willoughby; S L Buchan; S James; B Sheth; N R Smyth; G J Thomas; E C Y Wang; A Al-Shamkhani
Journal:  Mucosal Immunol       Date:  2010-10-20       Impact factor: 7.313

7.  Death receptor 3 is essential for generating optimal protective CD4⁺ T-cell immunity against Salmonella.

Authors:  Sarah L Buchan; Vadim Y Taraban; Tomasz J Slebioda; Sonya James; Adam F Cunningham; Aymen Al-Shamkhani
Journal:  Eur J Immunol       Date:  2012-01-19       Impact factor: 5.532

8.  Constitutive TL1A (TNFSF15) expression on lymphoid or myeloid cells leads to mild intestinal inflammation and fibrosis.

Authors:  David Q Shih; Robert Barrett; Xiaolan Zhang; Nicole Yeager; Hon Wai Koon; Piangwarin Phaosawasdi; Yahui Song; Brian Ko; Michelle H Wong; Kathrin S Michelsen; Gislaine Martins; Charalabos Pothoulakis; Stephan R Targan
Journal:  PLoS One       Date:  2011-01-11       Impact factor: 3.240

9.  The TNF-family cytokine TL1A drives IL-13-dependent small intestinal inflammation.

Authors:  F Meylan; Y-J Song; I Fuss; S Villarreal; E Kahle; I-J Malm; K Acharya; H L Ramos; L Lo; M M Mentink-Kane; T A Wynn; T-S Migone; W Strober; R M Siegel
Journal:  Mucosal Immunol       Date:  2010-10-27       Impact factor: 7.313

10.  An essential role for death receptor 3 in experimental autoimmune uveoretinitis.

Authors:  Claudia J Calder; Eddie C Y Wang
Journal:  Ocul Immunol Inflamm       Date:  2012-04-09       Impact factor: 3.070

View more
  26 in total

1.  On death receptor 3 and its ligands….

Authors:  Eddie C Y Wang
Journal:  Immunology       Date:  2012-09       Impact factor: 7.397

2.  Human group3 innate lymphoid cells express DR3 and respond to TL1A with enhanced IL-22 production and IL-2-dependent proliferation.

Authors:  Yong-Oon Ahn; Matthew A Weeres; Marie-Luise Neulen; Jahyang Choi; Seong-Ho Kang; Dae Seog Heo; Rachel Bergerson; Bruce R Blazar; Jeffrey S Miller; Michael R Verneris
Journal:  Eur J Immunol       Date:  2015-06-22       Impact factor: 5.532

Review 3.  The TNF-family cytokine TL1A: from lymphocyte costimulator to disease co-conspirator.

Authors:  Arianne C Richard; John R Ferdinand; Françoise Meylan; Erika T Hayes; Odile Gabay; Richard M Siegel
Journal:  J Leukoc Biol       Date:  2015-07-17       Impact factor: 4.962

4.  Death Receptor 3 Promotes Chemokine-Directed Leukocyte Recruitment in Acute Resolving Inflammation and Is Essential for Pathological Development of Mesothelial Fibrosis in Chronic Disease.

Authors:  William V Perks; Ravinder K Singh; Gareth W Jones; Jason P Twohig; Anwen S Williams; Ian R Humphreys; Philip R Taylor; Simon A Jones; Eddie C Y Wang
Journal:  Am J Pathol       Date:  2016-09-21       Impact factor: 4.307

Review 5.  The TNF Receptor Superfamily in Co-stimulating and Co-inhibitory Responses.

Authors:  Lindsay K Ward-Kavanagh; Wai Wai Lin; John R Šedý; Carl F Ware
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

Review 6.  Combination cancer immunotherapy and new immunomodulatory targets.

Authors:  Kathleen M Mahoney; Paul D Rennert; Gordon J Freeman
Journal:  Nat Rev Drug Discov       Date:  2015-08       Impact factor: 84.694

7.  Cleavage of TL1A Differentially Regulates Its Effects on Innate and Adaptive Immune Cells.

Authors:  John R Ferdinand; Arianne C Richard; Françoise Meylan; Aymen Al-Shamkhani; Richard M Siegel
Journal:  J Immunol       Date:  2018-01-15       Impact factor: 5.422

8.  The TNF-family ligand TL1A and its receptor DR3 promote T cell-mediated allergic immunopathology by enhancing differentiation and pathogenicity of IL-9-producing T cells.

Authors:  Arianne C Richard; Cuiyan Tan; Eric T Hawley; Julio Gomez-Rodriguez; Ritobrata Goswami; Xiang-Ping Yang; Anthony C Cruz; Pallavi Penumetcha; Erika T Hayes; Martin Pelletier; Odile Gabay; Matthew Walsh; John R Ferdinand; Andrea Keane-Myers; Yongwon Choi; John J O'Shea; Aymen Al-Shamkhani; Mark H Kaplan; Igal Gery; Richard M Siegel; Françoise Meylan
Journal:  J Immunol       Date:  2015-03-18       Impact factor: 5.422

9.  A Novel Role for TL1A/DR3 in Protection against Intestinal Injury and Infection.

Authors:  Li-Guo Jia; Giorgos Bamias; Kristen O Arseneau; Linda C Burkly; Eddy C Y Wang; Dennis Gruszka; Theresa T Pizarro; Fabio Cominelli
Journal:  J Immunol       Date:  2016-05-27       Impact factor: 5.422

10.  TL1A-DR3 Plasma Levels Are Predictive of HIV-1 Disease Control, and DR3 Costimulation Boosts HIV-1-Specific T Cell Responses.

Authors:  Bruna Oriol-Tordera; Alex Olvera; Clara Duran-Castells; Anuska Llano; Beatriz Mothe; Marta Massanella; Judith Dalmau; Carmela Ganoza; Jorge Sanchez; Maria Luz Calle; Bonaventura Clotet; Javier Martinez-Picado; Eugènia Negredo; Julià Blanco; Dennis Hartigan-O'Connor; Christian Brander; Marta Ruiz-Riol
Journal:  J Immunol       Date:  2020-11-11       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.